Local Evidence and Investment Prioritisation Framework Diagnostic Review
Do your evidence priorities reflect local decision needs, align with global plans and direct investment to the gaps that matter most?
When evidence needs compete for limited resources, the problem is not always a shortage of funding or the quality of individual study proposals. It may lie in how local needs are assessed, priorities are agreed, and responsibilities are shared across Medical Affairs, Evidence, Market Access and global teams.
Point Lumina’s review
Point Lumina’s facilitated diagnostic review helps maximise Medical Affairs value by identifying operating model friction points and giving leaders clarity on where to focus effort, how to improve decisions, and how to deliver impact where it matters most.
Who is this service for?
For local and regional Medical Affairs, Evidence Generation, HEOR and Market Access leaders, local affiliate leadership teams, and global partners who need a shared basis for prioritising local evidence needs and allocating resources.
What you gain
A clear leadership-level assessment of where local evidence needs become disconnected from agreed priorities and investment decisions.
A practical basis for comparing competing needs using explicit criteria such as decision relevance, urgency, feasibility and the consequences of leaving a gap unresolved, etc.
Streamlined process for bringing local clinical and payer requirements into global evidence planning early enough to influence commitments.
Clearer responsibilities across Medical Affairs, Evidence Generation, HEOR, Market Access and global partners.
Recommendations for clarifying who can prioritise, fund, defer or stop proposals, and how unresolved disagreements should be escalated.
An independent assessment of whether focused changes to criteria or planning interfaces are sufficient, or broader redesign of the prioritisation framework is warranted.
Clear priorities for action: which assessment, planning and investment decisions to strengthen first, with a practical route to implementation.
*Further strategic advice or implementation support is available separately, where useful.
“Arnas led the new ways of working with agility and clarity, enabling the Evidence Team to focus on the most critical priorities while the organisation transitioned to the new operating model.” — Evidence Director, Pharmaceutical organisation, former colleague.